Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 19.6 | 22.2 | 30.2 | 19.9 | 13.1 |
| Revenue growth | -11.5% | | 51.9% | 52.3% | |
| Cost of goods sold | 35.3 | 78.8 | 0.0 | 0.0 | 0.0 |
| Gross profit | -15.7 | -56.6 | 30.2 | 19.9 | 13.1 |
| Gross margin | -79.8% | -255.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 10.7 | 53.9 | 23.7 | 16.9 | 11.4 |
| General and administrative | 24.7 | 25.0 | 6.5 | 3.0 | 1.6 |
| EBIT | -15.7 | -56.6 | -30.1 | -19.8 | -12.9 |
| EBIT margin | -79.8% | -255.0% | -99.8% | -99.7% | -99.0% |
| Pre-tax income | -29.9 | -52.8 | -30.2 | -19.9 | -12.8 |
| Income taxes | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | 0.0% | 0.0% |
| Net income | -29.9 | -53.0 | -30.2 | -19.9 | -12.8 |
| Net margin | -152.3% | -238.6% | -100.0% | -99.9% | -98.1% |
| |
| Diluted EPS | ($0.32) | ($0.70) | ($1.40) | ($1.87) | ($1.41) |
| Shares outstanding (diluted) | 92.1 | 75.3 | 21.6 | 10.6 | 9.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|